Terms: = Breast cancer AND MSN, P26038, 4478, ENSG00000147065
76 results:
1. PEGylated mesoporous silica core-shell redox-responsive nanoparticles for delivering paclitaxel to breast cancer cells.
Shahbaz S; Esmaeili M; Fathian Nasab MH; Imani Z; Bafkary R; Amini M; Atyabi F; Dinarvand R
Int J Pharm; 2024 Apr; 655():124024. PubMed ID: 38537920
[TBL] [Abstract] [Full Text] [Related]
2. Programmed Co-delivery of tamoxifen and docetaxel using lipid-coated mesoporous silica nanoparticles for overcoming CYP3A4-mediated resistance in triple-negative breast cancer treatment.
Wang Y; Cheng W; Zhu J; He L; Ren W; Bao D; Piao JG
Biomed Pharmacother; 2024 Jan; 170():116084. PubMed ID: 38157645
[TBL] [Abstract] [Full Text] [Related]
3. Cytotoxic and DNA-binding Capacity of Titanocene Functionalized Mesoporous Nanoparticles in breast cancer Cell Lines MCF-7 and MDA-MB-231.
Serrano-Pindado Á; Iorhemba MA; Díaz-García D; Díaz-Sánchez M; Mena-Palomo I; Gómez-Ruiz S; Prashar S
Curr Pharm Des; 2023; 29(22):1791-1799. PubMed ID: 37518995
[TBL] [Abstract] [Full Text] [Related]
4. Co-Delivery of Silymarin and Metformin Dual-Loaded in Mesoporous Silica Nanoparticles Synergistically Sensitizes breast cancer Cell Line to Mitoxantrone Chemotherapy.
Rezaei Harandi Z; Heidari R; Reiisi S
IEEE Trans Nanobioscience; 2023 Oct; 22(4):872-880. PubMed ID: 37022888
[TBL] [Abstract] [Full Text] [Related]
5. Intracellular and extracellular moesins differentially regulate Src activity and β-catenin translocation to the nucleus in breast cancer cells.
Ahandoust S; Li K; Sun X; Li BY; Yokota H; Na S
Biochem Biophys Res Commun; 2023 Jan; 639():62-69. PubMed ID: 36470073
[TBL] [Abstract] [Full Text] [Related]
6. Targeted delivery and apoptosis induction activity of peptide-transferrin targeted mesoporous silica encapsulated resveratrol in MCF-7 cells.
Li D; Song C; Zhang J; Zhao X
J Pharm Pharmacol; 2023 Jan; 75(1):49-56. PubMed ID: 36173891
[TBL] [Abstract] [Full Text] [Related]
7. Mannosylated poly(acrylic acid)-coated mesoporous silica nanoparticles for anticancer therapy.
Lee H; Choi M; Kim HE; Jin M; Jeon WJ; Jung M; Yoo H; Won JH; Na YG; Lee JY; Seong H; Lee HK; Cho CW
J Control Release; 2022 Sep; 349():241-253. PubMed ID: 35798094
[TBL] [Abstract] [Full Text] [Related]
8. Near-Infrared-Enpowered Nanomotor-Mediated Targeted Chemotherapy and Mitochondrial Phototherapy to Boost Systematic Antitumor Immunity.
Zhang X; He Q; Sun J; Gong H; Cao Y; Duan L; Yi S; Ying B; Xiao B
Adv Healthc Mater; 2022 Jul; 11(14):e2200255. PubMed ID: 35536883
[TBL] [Abstract] [Full Text] [Related]
9. A pH-responsive mesoporous silica nanoparticle-based drug delivery system for targeted breast cancer therapy.
Chang J; Mo L; Song J; Wang X; Liu H; Meng C; Wu Y
J Mater Chem B; 2022 May; 10(17):3375-3385. PubMed ID: 35388835
[TBL] [Abstract] [Full Text] [Related]
10. Enhancement of anti-neoplastic effects of cuminaldehyde against breast cancer via mesoporous silica nanoparticle based targeted drug delivery system.
Ghosh S; Kundu M; Dutta S; Mahalanobish S; Ghosh N; Das J; Sil PC
Life Sci; 2022 Jun; 298():120525. PubMed ID: 35378139
[TBL] [Abstract] [Full Text] [Related]
11. Mesoporous Silica Nanoparticle-Based Combination of Niclosamide and Doxorubicin: Effect of Treatment Regimens on breast cancer Subtypes.
Lohiya G; Katti DS
ACS Appl Bio Mater; 2021 Nov; 4(11):7811-7824. PubMed ID: 35006763
[TBL] [Abstract] [Full Text] [Related]
12. Suppression of breast cancer-associated bone loss with osteoblast proteomes via Hsp90ab1/moesin-mediated inhibition of TGFβ/FN1/CD44 signaling.
Sun X; Li K; Hase M; Zha R; Feng Y; Li BY; Yokota H
Theranostics; 2022; 12(2):929-943. PubMed ID: 34976221
[No Abstract] [Full Text] [Related]
13. Carboxylated chitosan-mediated improved efficacy of mesoporous silica nanoparticle-based targeted drug delivery system for breast cancer therapy.
Lohiya G; Katti DS
Carbohydr Polym; 2022 Feb; 277():118822. PubMed ID: 34893239
[TBL] [Abstract] [Full Text] [Related]
14. Effective Triple-Negative breast cancer Targeted Treatment Using iRGD-Modified RBC Membrane-Camouflaged Nanoparticles.
Huang J; Lai W; Wang Q; Tang Q; Hu C; Zhou M; Wang F; Xie D; Zhang Q; Liu W; Zhang Z; Zhang R
Int J Nanomedicine; 2021; 16():7497-7515. PubMed ID: 34803378
[TBL] [Abstract] [Full Text] [Related]
15. Tumour-Targeted and Redox-Responsive Mesoporous Silica Nanoparticles for Controlled Release of Doxorubicin and an siRNA Against Metastatic breast cancer.
Zhuang J; Chen S; Hu Y; Yang F; Huo Q; Xie N
Int J Nanomedicine; 2021; 16():1961-1976. PubMed ID: 33727809
[TBL] [Abstract] [Full Text] [Related]
16. Cinnamaldehyde and Doxorubicin Co-Loaded Graphene Oxide Wrapped Mesoporous Silica Nanoparticles for Enhanced MCF-7 Cell Apoptosis.
Dong K; Zhao ZZ; Kang J; Lin LR; Chen WT; Liu JX; Wu XL; Lu TL
Int J Nanomedicine; 2020; 15():10285-10304. PubMed ID: 33376322
[TBL] [Abstract] [Full Text] [Related]
17. Biodegradable nanocarriers based on chitosan-modified mesoporous silica nanoparticles for delivery of methotrexate for application in breast cancer treatment.
Shakeran Z; Keyhanfar M; Varshosaz J; Sutherland DS
Mater Sci Eng C Mater Biol Appl; 2021 Jan; 118():111526. PubMed ID: 33255079
[TBL] [Abstract] [Full Text] [Related]
18. Tumor targeting antibody-conjugated nanocarrier with pH/thermo dual-responsive macromolecular film layer for enhanced cancer chemotherapy.
Zhuang J; Zhou L; Tang W; Ma T; Li H; Wang X; Chen C; Wang P
Mater Sci Eng C Mater Biol Appl; 2021 Jan; 118():111361. PubMed ID: 33254980
[TBL] [Abstract] [Full Text] [Related]
19. Targeted delivery of curcumin in breast cancer cells via hyaluronic acid modified mesoporous silica nanoparticle to enhance anticancer efficiency.
Ghosh S; Dutta S; Sarkar A; Kundu M; Sil PC
Colloids Surf B Biointerfaces; 2021 Jan; 197():111404. PubMed ID: 33142257
[TBL] [Abstract] [Full Text] [Related]
20. A nanoplatform based on mesoporous silica-coated gold nanorods for cancer triplex therapy.
Liu G; Liang H; He Y; Lu L; Wang L; Liu P; Cai K
J Mater Chem B; 2020 Nov; 8(42):9686-9696. PubMed ID: 33030156
[TBL] [Abstract] [Full Text] [Related]
[Next]
